drugset / Trial / NCT02987946

Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events

NCT02987946

RandomizedParallel-groupOpen-labelPrevention

Summary

In neurosurgical patients, the risk for venous thromboembolic events (VTE) is high due to the relatively long duration of surgery, the high occurrence of prolonged immobilization of patients due to paresis of the legs or intracranial pathology causing inability to mobilise2. Moreover, intracranial and intraspinal tumours and subarachnoid haemorrhage cause hypercoagulability, which increases the risk on VTE. There is a high degree of diversity in attributed risk on thrombosis in the neurosurgical patient cohort. Due to this diversity, insufficient power of performed studies and lack of careful phenotyping and description of risk factors in previous studies on deep venous thrombosis (DVT) prophylaxis, as yet the optimal DVT prophylaxis in neurosurgery remains unclear. A prospective randomized study with adequate power and detailed information on patient related factors (malignancy, subarachnoid haemorrhage, prevailing coagulopathies), type of surgery, duration of surgery, and postoperative immobilisation will allow us to identify the optimal treatment strategy for high risk neurosurgical patients. In the current study all patients that fulfil the inclusion criteria will be subjected to post-operative systematic evaluation of VTE by echo-duplex investigation.

Timeline

Start
2016-12
Primary completion
2023-12
Completion
2024-09

Drugs

EvaluationDrugModalityDoseRoute
Background Nadroparin Calcium Other / unclassified 2850 iu
Background Nadroparin Calcium Other / unclassified 5600 iu